Nipro Markets Human iPS Cell Products To Pharmaceutical Companies In Japan
This article was originally published in PharmAsia News
Executive Summary
Japanese drug and device maker Nipro June 1 launched cardiomyocytes made from induced pluripotent stem cells to research institutions and pharmaceutical companies for cardiac research and new drug development. The first commercial products made from human iPS cells in Japan, the cardiomyocytes are manufactured by Tokyo-based biotech venture company ReproCell. Nipro signed a licensing agreement and obtained exclusive rights in Japan. Priced at ¥300,000 each kit consists of five cell clusters, Nipro estimates ¥20-¥50 million in annual sales. The cardiotoxicity assay allows the direct measurement of parameters in an invitro functional assay that comes close to invivo conditions. (Click here for more - Japanese language
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.